Aptorum Group Stock Soars 159% On DiamiR Test Approval

(RTTNews) - Aptorum Group Limited (APM) surged 159.45 percent to $3.29, up $2.02 on Thursday, after its partner DiamiR Biosciences received Clinical Laboratory Evaluation Program approval from the New York State Department of Health for its APOE Genotyping test.

Shares opened at $2.71 and traded between $2.40 and $3.84 on massive volume of 270.9 million shares, compared with the average of 3.3 million on the Nasdaq. The stock's 52-week range is $0.46 to $7.49.

The approval allows DiamiR to provide validated molecular testing for brain health through its CLIA-certified and CAP-accredited laboratory to healthcare providers in New York and across the U.S.